Operating Segments - Segment Revenues and Profit (Loss) (Details) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
|
Jun. 30, 2026
USD ($)
|
Jun. 30, 2025
USD ($)
|
Jun. 30, 2026
USD ($)
segment
|
Jun. 30, 2025
USD ($)
|
|
| Operating Segments | ||||
| Number of operating segments | segment | 2 | |||
| Number of reportable segments | segment | 2 | |||
| Research and development | $ 974,091 | $ 1,677,014 | $ 2,756,391 | $ 3,618,694 |
| General and administrative | 1,125,372 | 1,086,865 | 2,227,910 | 2,171,693 |
| Adjusted loss from operations | (2,099,463) | (2,763,879) | (4,984,301) | (5,790,387) |
| Share-based compensation | 237,180 | 163,112 | ||
| Loss from operations | (2,099,463) | (2,763,879) | (4,984,301) | (5,790,387) |
| Other income, net | 112,109 | 61,903 | 171,982 | 137,143 |
| Net loss before income taxes | (1,987,354) | (2,701,976) | (4,812,319) | (5,653,244) |
| Reportable segments | ||||
| Operating Segments | ||||
| Loss from operations | (874,365) | (1,554,250) | (2,567,251) | (3,390,940) |
| Reportable segments | Specialized BioTherapeutics | ||||
| Operating Segments | ||||
| Research and development | 831,614 | 1,523,099 | 2,476,711 | 3,273,701 |
| Adjusted loss from operations | (831,614) | (1,523,099) | (2,476,711) | (3,273,701) |
| Share-based compensation | 39,239 | 26,487 | 83,709 | 52,975 |
| Depreciation and amortization | 658 | 423 | 1,317 | 787 |
| Loss from operations | (871,511) | (1,550,009) | (2,561,737) | (3,327,463) |
| Net loss before income taxes | (871,511) | (1,550,009) | (2,561,737) | (3,327,463) |
| Reportable segments | Public Health Solutions | ||||
| Operating Segments | ||||
| Research and development | 2,745 | 3,332 | 5,295 | 61,667 |
| Adjusted loss from operations | (2,745) | (3,332) | (5,295) | (61,667) |
| Share-based compensation | 839 | 1,679 | ||
| Depreciation and amortization | 109 | 70 | 219 | 131 |
| Loss from operations | (2,854) | (4,241) | (5,514) | (63,477) |
| Net loss before income taxes | (2,854) | (4,241) | (5,514) | (63,477) |
| Corporate | ||||
| Operating Segments | ||||
| Research and development | 99,726 | 122,764 | 189,140 | 227,754 |
| General and administrative | 1,048,309 | 1,014,468 | 2,073,780 | 2,062,842 |
| Adjusted loss from operations | (1,148,035) | (1,137,232) | (2,262,920) | (2,290,596) |
| Share-based compensation | 76,733 | 72,187 | 153,471 | 108,458 |
| Depreciation and amortization | 330 | 210 | 659 | 393 |
| Loss from operations | (1,225,098) | (1,209,629) | (2,417,050) | (2,399,447) |
| Other income, net | 112,109 | 61,903 | 171,982 | 137,143 |
| Net loss before income taxes | (1,112,989) | (1,147,726) | (2,245,068) | (2,262,304) |
| Adjustments | ||||
| Operating Segments | ||||
| Research and development | 40,006 | 27,819 | 85,245 | 55,572 |
| General and administrative | 77,063 | 72,397 | 154,130 | 108,851 |
| Adjusted loss from operations | (117,069) | (100,216) | (239,375) | (164,423) |
| Share-based compensation | (115,972) | (99,513) | (237,180) | (163,112) |
| Depreciation and amortization | $ (1,097) | $ (703) | $ (2,195) | $ (1,311) |